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Edited by Ned ManteiAbstract Growth hormone (GH) is an important regulator of
adiposity and systemic energy metabolism. Here, we have
investigated the eﬀects of GH on production of adiponectin, an
anti-diabetic and anti-atherogenic hormone secreted exclusively
from adipocytes. Analysis using real time quantitative PCR
revealed that GH signiﬁcantly increased adiponectin gene
expression in a dose-dependent manner. Time course study
showed that the expression of adiponectin gene started to
increase only after 30 h of GH treatment (108 M), suggesting it
to be a chronic eﬀect. GH-mediated induction of adiponectin
gene expression was completely blocked by treatment with the
Janus kinase2 (JAK2) inhibitor AG490 and the P38 mitogen
activated protein (MAP) kinase inhibitor SB203580, while the
speciﬁc inhibitors of phosphatidylinositol-3-kinase (LY294002)
and p70S6 kinase (rapamycin) moderately enhanced GHs eﬀect.
Co-incubation of adipocytes with GH and the PPARc agonist
rosiglitazone produced additive eﬀects on induction of adiponec-
tin gene expression. These results collectively suggest that GH
increases adiponectin gene expression through the JAK2-P38
MAP kinase pathway, and that elevation of adiponectin
production might represent a novel mechanism by which GH
regulates systemic energy metabolism and insulin sensitivity.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Adipose tissue is now recognized to be an important endo-
crine organ, secreting a variety of polypetides (adipokines) that
are involved in the regulation of energy metabolism, immune
response and cardiovascular tone [1,2]. Adiponectin (also
called ACRP30, adipoQ or Apm1) is an important adipokine
exclusively secreted from adipose tissue [3]. This protein be-
longs to the soluble defense collagen superfamily that contains
a modular design comprising an NH2-terminal collagen-repeat
domain and a COOH-terminal, characteristic complement
factor C1q-like globular head domain. Growing evidence
suggests that adiponectin is an insulin-sensitizing hormone
with direct anti-diabetic, anti-atherogenic and anti-inﬂamma-
tory potentials [2,3].* Corresponding author. Fax: +852-28162095.
E-mail address: amxu@hkucc.hku.hk (A. Xu).
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.07.020It has been demonstrated that both central and peripheral
administration of recombinant adiponectin cause sustained
weight loss in mice without reducing food intake [4,5]. Injec-
tion of recombinant full-length adiponectin produced from
mammalian cells abolishes hyperglycemia in several diabetic
animal models, possibly through downregulation of the he-
patic expression of the gluconeogenic enzymes [6]. Chronic
treatment with adiponectin could restore insulin sensitivity in
both high fat (HF) fed and lipoatropic mice, by increasing b-
oxidation of fatty acid in muscle, and thus decreasing muscular
triglyceride content [7]. Furthermore, adenovirus-mediated
expression of adiponectin alleviates atherosclerosis in apoE
deﬁcient mice. We have recently found that chronic adminis-
tration of recombinant full-length adiponectin generated from
mammalian cells can alleviate alcoholic and non-alcoholic
fatty liver diseases associated with obese ob/ob mice, and can
also ameliorate dyslipidemia and insulin resistance in these
animal models [8]. In vitro studies have shown that re-
combinant adiponectin can prevent foam cell formation [9],
inhibit the proliferation of smooth muscle cells seen when they
are stimulated by various growth factors [10], and protect
pancreatic islet b cells from apoptosis [11]. Two more recent
independent knockout studies showed that depletion of
adiponectin expression in mice causes moderate insulin resis-
tance, glucose intolerance and increased neointimal formation
following mechanical injury [12,13], suggesting that adipo-
nectin deﬁciency is one of the major contributors to the cau-
sation of these metabolic disorders.
Plasma levels of adiponectin correlate closely with systemic
insulin sensitivity, and decreased adiponectin concentrations
(hypoadiponectinemia) were observed in patients with type 2
diabetes, insulin resistance or coronary heart disease [14–16].
Several prospective studies suggest that a decline in plasma
adiponectin concentration preceded the decrease in insulin
sensitivity, suggesting that adiponectin deﬁciency might be an
important causative factor of insulin resistance [17,18]. Indeed,
several insulin resistance inducing factors, such as tumor ne-
crosis factor a, interleukin 6, dexmethasone and isoproterenol,
have been shown to reduce adiponectin production [19–21]. On
the other hand, the PPARc agonists thiazolidinediones (TZD),
which are used clinically as insulin sensitizing drugs, could
increase adiponectin expression and its plasma concentrations
in rodents and human subjects [22,23].
Growth hormone (GH) is an important regulator of sys-
temic energy metabolism and insulin sensitivity [24]. Adipose
tissue is one of the major targets of GH, where both full-length
and the truncated GH receptors are expressed [25]. Opposingation of European Biochemical Societies.
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ported in adipocytes: acute insulin-like eﬀects and chronic in-
sulin-antagonizing eﬀects [24]. In the present study, we
investigated the direct eﬀect of GH on adiponectin production
from adipocytes. Our results revealed that chronic treatment
with GH could increase adiponectin production in a time- and
dose-dependent manner. GH-induced adiponectin expression
was completely blocked by the Janus kinase2 (JAK2) speciﬁc
inhibitor AG490 and the P38 mitogen activated protein
(MAP) kinase inhibitor SB203580. Furthermore, we observed
that insulin inhibited the action of GH on adiponectin gene
expression.2. Materials and methods
2.1. Materials
Insulin, dexamethasone, methyl-isobutyl-xanthine, PD98059,
SB203580 and LY294002 were purchased from Sigma (Saint Louis,
MO, USA). Genestein and AG490 are products of Calbiochem (La
Jolla, CA, USA). Human recombinant GH and rosiglitazone were
obtained from Lilly France (S.A. Fersheim, France) and Alexis Bio-
chemicals (Lausanne, Switzerland), respectively. Trizol Reagent, Su-
perscript ﬁrst-strand cDNA synthesis system and lipofectamine 2000
were purchased form Invitrogen (Carlsbad, CA, USA). Dual luciferase
reporter system and the reporter vectors pGL3-basic and pRL-CMV
are the products of Promega Corporation (Madison, USA).
2.2. Cell culture and diﬀerentiation
3T3-L1 cells were maintained as subconﬂuent cultures in Dubecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal bovine serum.
Adipocyte diﬀerentiation was induced as we previously described [26].
2.3. Analysis of adiponectin gene expression by Northern blot and real
time quantitative RT-PCR
Total RNA was extracted from 3T3-L1 adipocytes using Trizol
Reagents according to the manufacturer’s instructions. 1 lg of total
RNA was transcribed into cDNA with the Superscript ﬁrst-strand
cDNA synthesis system. Taqman real-time quantitative PCR was
conducted according to the manufacturer’s instructions (Applied
Biosystems, Foster, CA, USA). Northern blot analysis of the
adiponectin gene abundance was performed as we previously described
[27].
2.4. Quantiﬁcation of adiponectin concentration by ELISA
The conditioned culture medium from 3T3-L1 adipocytes treated
without or with GH (108 M) was collected at diﬀerent time points,
diluted with PBS containing 1% BSA, and then quantiﬁed using a
sandwich ELISA method as we previously described [27].
2.5. Cloning of mouse adiponectin promoter and construction of the
luciferase reporter vector
Mouse genomic DNA extracted from 3T3-L1 adipocytes was used as
template for PCR ampliﬁcation. A 1.0 kb promoter segment corre-
sponding to )1037 to +19 bp of the mouse adiponectin gene was
ampliﬁed using the forward primer CGATTGCTAGCCCTTTTAG-
GAGCAGTTTAGTGAGTG and the reverse primer AGTCA-
CTCGAGGTCAGATCCACTGACAATCGTACAG, respectively.
The DNA fragment was digested with NheI and XhoI, and subcloned
into PGL3-basic vector. The sequence of the cloned DNA fragment
was conﬁrmed by DNA sequencing.
2.6. Transient transfection and luciferase reporter assays
3T3-L1 adipocytes at day 7 after diﬀerentiation were transfected
with the luciferase reporter vectors using Lipofectamine 2000. Lucif-
erase assays were conducted using the Dual-Luciferase Reporter sys-
tem (Promega). Transiently transfected cells were solubilized in 100 ll
of lysis buﬀer. After centrifugation to remove cell debris, 20 ll of the
cell lysate was used to measure luciferase activity according to the
manufacturer’s instructions. In each measurement, luciferase units
were normalized for background and for transfection eﬃciency asdetermined by the ‘Renilla’ luciferase activity of the co-transfected
pRL-CMV plasmid.
2.7. Statistical analysis
Results were reproduced in at least four independent experiments.
The results are presented as means of at least triplicate determinations
S.D. Signiﬁcance was determined by Student’s t test or one-way
ANOVA. In all statistical comparisons, a P value of less than 0.05 was
considered statistically signiﬁcant.3. Results
3.1. GH induces expression of adiponectin gene in a time- and
dose-dependent manner in 3T3-L1 adipocytes
To evaluate the eﬀect of GH on adiponectin gene expres-
sion, we treated 3T3-L1 adipocytes with diﬀerent concentra-
tions of GH for 40 h. Real time quantitative PCR analysis
revealed that several dosages of GH (from 1011 to 107 M)
signiﬁcantly increased adiponectin gene expression, while su-
pra-physiological concentration of GH (106 M) had no
obvious eﬀect (Fig. 1A). This result was further conﬁrmed by
Northern blot analysis (Fig. 1B). GH treatment under exactly
the same condition did not inﬂuence the mRNA expression
of aP2 and PPARc, the two well-established diﬀerentiation
markers of adipocytes, suggesting that GH-induced adipo-
nectin gene expression is not due to its eﬀect on adipogenesis
(Fig. 1C).
A time course study revealed that a signiﬁcant induction
of adiponectin gene expression was detected only after 30 h
of GH treatment, and reached a maximum after 40 h
(Fig. 2A), suggesting GH action on adiponection expression
to be of a chronic nature. Quantitative ELISA analysis
demonstrated that adiponectin concentrations in the condi-
tioned medium were signiﬁcantly increased only at 40 h after
GH treatment (Fig. 2B). The maximal elevation was de-
tected at 60 h after GH treatment. This result suggests that
the increase of adiponectin secretion follows behind the GH-
induced elevation of adiponectin gene expression in 3T3-L1
adipocytes.3.2. GH-induced expression of adiponectin gene is blocked by
inhibition of the JAK2-P38 MAP kinase pathway
GH initiates its multiple biological eﬀects by inducing di-
merization of its receptor followed by activation of JAK2.
Activated JAK2 is responsible for tyrosine phosphorylation of
the GH receptors and subsequent activation of several kinases,
including phosphatidylinositol-3 (PI-3)-kinase, P44/42 MAP
kinase and P38 MAP kinase [25]. p70S6 kinase is an important
signaling protein downstream of PI-3-kinase implicated in the
regulation of protein synthesis [28]. We next investigated the
role of these signaling pathways on GH-induced adiponectin
gene expression, by using speciﬁc inhibitors of the aforemen-
tioned kinases. GH-mediated induction of adiponectin gene
expression was completely blocked by either the JAK2 inhib-
itor AG490, the tyrosine kinase inhibitor genestein or the P38
MAP kinase inhibitor SB203586 (Fig. 3). The P42/44 MAP
kinase inhibitor PD98059 had no obvious eﬀect. On the other
hand, treatment with the PI-3-kinase inhibitor LY294002 and
the p70S6 kinase inhibitor rapamycin enhanced the action of
GH on induction of the adiponectin gene expression, sug-
gesting that PI-3-kinase/p70S6 kinase pathway is a suppressor
of adiponectin gene expression.
Fig. 1. Eﬀects of GH on expression of the adiponectin, aP2 and
PPARc genes in 3T3-L1 adipocytes. In panel A, 3T3-L1 adipocytes
(day 7 after diﬀerentiation) were untreated or treated with diﬀerent
concentrations of GH for 40 h. Total RNA puriﬁed from these samples
was subjected to quantitative PCR analysis to determine the levels of
adiponectin gene expression as described in Section 2.3. The steady
state abundance of adiponectin RNA is expressed relative to untreated
control cells. *, P < 0:05 and **, P < 0:01 versus untreated samples
(n ¼ 6). Panel B is a representative autoradiogram from Northern blot
analysis of adiponectin RNA (n ¼ 5). Panel C, the steady state
abundance of aP2 and PPARc RNA from 3T3-L1 adipocytes treated
without or with GH (108) for 40 h was analyzed by quantitative PCR
as in panel A (n ¼ 5).
Fig. 2. Time-dependent induction of adiponectin gene expression and
protein secretion by GH. (A) 3T3-L1 adipocytes were treated without
or with 108 M GH for the indicated periods of time. The relative
abundance of adiponectin RNA was determined by quantitative PCR.
(B) The cells were treated as in panel A. An aliquot of the conditioned
medium was collected at each time point and then subjected to ELISA
analysis of adiponectin concentration, as we previously described [27].
For comparison, the levels of the adiponectin RNA (panel A) and
protein concentration (panel B) from each time point of the untreated
samples were arbitrarily set at 1. *, P < 0:05 and **, P < 0:01 versus
untreated samples in each time point (n ¼ 4–6).
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distinct pathways
The expression of adiponectin has been shown to be under
the control of the transcription factor PPARc [29]. The
PPARc agonists TZD can increase plasma adiponectin levels
in humans and mice [22]. Consistent with previous reports,
we found that the PPARc agonist rosiglitazone enhanced
adiponectin mRNA expression by 1.8-fold (Fig. 4A), while
GH increased adiponectin gene expression by 2-fold. Co-
incubation of cells with GH and rosiglitazone elevated the
steady state mRNA abundance of adiponectin gene by 4-
fold, suggesting that the eﬀects of GH and rosiglizatone on
adiponectin gene expression are additive. Furthermore,treatment of adipocytes with rosiglitazone enhanced the ac-
tivity of the )1.0 kb mouse adiponectin gene promoter by
2.8-fold, whereas GH had no signiﬁcant eﬀect. These results
suggest that GH and the PPARc agonist induce adiponectin
gene expression through distinct mechanisms.3.4. GH and insulin exert opposite eﬀects on adiponectin gene
expression in 3T3-L1 adipocytes
Insulin has been shown to be a negative regulator of
adiponectin gene expression [20,30]. Insulin and GH exert
many opposite eﬀects on adipocytes, including lipolysis, li-
pogenesis and glucose uptake [24]. Here, we investigated the
interactions between GH and insulin on adiponectin gene
expression. Consistent with previous reports, treatment of
adipocytes with 10 nM of insulin alone signiﬁcantly de-
creased expression level of the adiponectin gene (Fig. 5). In
addition, GH-induced adiponectin gene expression was
completely blocked by insulin treatment.
Fig. 4. GH and rosiglitazone augmented adiponectin gene expression
through diﬀerent pathways. In panel A, 3T3-L1 adipocytes were un-
treated (control), or treated with 10 lM rosiglitazone (Rosi), 108 M
GH, or 10 lM rosiglitazone plus 108 M GH for 40 h. Adiponectin
RNA was quantiﬁed as described in Fig. 1. *, P < 0:01 versus control;
##, P < 0:01 versus samples treated with GH or Rosi alone (n ¼ 4–6).
In panel B, 3T3-L1 adipocytes grown in a 12-well dish were transfected
with the luciferase reporter vector driven by the 1.0 kb adiponectin
promoter plus PRL-CMV plasmid. 4 h after transfection, the cells were
treated as in panel A. Fireﬂy and Renilla luciferase reporter activity
was measured as described in Section 2.5. The adiponectin promoter
activity was normalized by pRL-CMV Renilla luciferase activity.
*, P < 0:01 versus control (n ¼ 4).
Fig. 3. Eﬀects of diﬀerent pharmacological inhibitors on GH-mediated
induction of adiponectin gene expression. 3T3-L1 adipocytes were
untreated (control), or treated with GH, or GH plus 25 lM genestein,
25 lMPD98059, 25 lM SB203586, 25 lMAG490, 1 lM rapamycin or
10 lM LY294002. 40 h after the treatment, 1 lg of total RNA from
each sample was subjected to quantitative PCR analysis of adiponectin
RNA. **, P < 0:01 versus control; ##, P < 0:05 and #, P < 0:01 versus
GH treated samples (n ¼ 6–8). Note that none of these pharmaco-
logical inhibitors signiﬁcantly aﬀect the basal mRNA expression of the
adiponectin gene (data not shown).
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GH is now recognized to be an important regulator of sys-
temic metabolism and glucose homeostasis. Although several
studies have demonstrated that exogenous administration of
supra-physiological doses of GH results in diabetogenic eﬀects
[31], it has also been demonstrated that GH can decrease hy-
perglycemia and improve insulin sensitivity [32,33]. GH sup-
plement therapy in both obese individuals and GH deﬁcient
subjects has shown various beneﬁcial eﬀects, especially in de-
creasing body fat percentage and in improving lipid metabo-
lism, though the long-term outcome of this treatment remains
to be established.
In addition to its role in regulating glucose and lipid me-
tabolism [25], GH has been shown to modulate the production
of adipocyte-derived adipokines, such as leptin and resistin
[34,35]. In the present study, we demonstrated that chronic
treatment of 3T3-L1 adipocytes with physiological concen-
trations of GH led to a dose-dependent induction of
adiponectin gene expression (Fig. 1). This induction was time-
dependent, being observed only after 30 h of GH treatment,
reaching a maximum after 40 h (Fig. 2). In keeping with these
ﬁndings, no eﬀect of GH on adiponectin mRNA levels was
observed in a previous study in which 3T3-L1 cells were
treated with GH for 16 h [20]. Our ﬁndings suggest that an
induction of adiponectin gene expression could constitute one
mechanism, whereby treatment with physiological doses of
GH leads to improved insulin sensitivity in GH deﬁcient
insulin resistant adults [33]. Indeed, in a recent study, a rise in
serum adiponectin was observed following GH replacement in
women with GH deﬁciency [35].
Although the net outcome of GH stimulation at several
dosages is to increase steady-state mRNA abundance of the
adiponectin gene, several signaling pathways evoked by this
hormone appear to play opposite roles. Treatment with
the P38 MAP kinase inhibitor SB203580 led to the complete
inhibition of GH-induced adiponectin gene expression, sug-
gesting that this kinase is a positive regulator of adiponectingene expression. On the other hand, GH-induced elevation of
adiponectin gene expression was further enhanced by treat-
ment with the inhibitors of PI-3-kinase or p70S6 kinase, in-
dicating that activation of PI-3-kinase/p70S6 kinase pathway
suppresses the expression of this gene. The opposing actions of
these two GH-induced pathways could explain why supra-
physiological concentration of GH (106) had no obvious
eﬀect on adiponectin gene expression (Fig. 1). Given the
existence of both full-length and truncated forms of GH re-
ceptors with diﬀerent aﬃnities in adipocytes [36], it is possible
that diﬀerent concentrations of GH can diﬀerentially activate
the aforementioned kinase pathways. Upon treatment with a
supra-physiological concentration of GH (106), the P38 MAP
kinase pathway-mediated positive regulation of adiponectin
gene expression might be completely counteracted by the
negative eﬀect of the PI-3-kinase/p70S6 pathway.
Our ﬁnding that insulin can inhibit the GH-induced eleva-
tion of the adiponectin gene expression further supports the
negative role of PI-3-kinase/p70S6 kinase pathway in this
process (Fig. 5). Several recent studies demonstrated that in-
Fig. 5. GH-induced adiponectin gene expression is suppressed by in-
sulin. 3T3-L1 adipocytes were untreated, or treated with 108 GH, 10
nM insulin plus 108 GH, or 10 nM insulin alone. 40 h after treatment,
the steady state abundance of adiponectin RNA was quantiﬁed as in
Fig. 1. **, P < 0:01 versus control; ##, P < 0:01 versus GH treated
group (n ¼ 4–6).
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vitro as well as in vivo [20,30]. Clinical data revealed that there
is an inverse relationship between plasma levels of insulin and
adiponectin [16]. Furthermore, infusion of insulin into healthy
individuals can cause a signiﬁcant reduction of plasma
adiponectin. The role of insulin as a negative regulator of
adiponectin production was further conﬁrmed by the ﬁnding
that adipose tissue-speciﬁc ablation of the insulin receptor
resulted in increased plasma adiponectin levels and systemic
insulin sensitivity [37]. It has been proposed that hyperinsuli-
nemia is at least partly responsible for hypoadiponectinemia
during the dynamic phase of insulin resistance. In line with our
ﬁnding, a previous study has found that inhibition of either
PI-3-kinase or p70S6 using their speciﬁc pharmacological in-
hibitors partially reversed insulin-mediated suppression of
adiponectin gene expression [20]. Co-incubation of GH with
insulin will therefore lead to further activation of the PI-3-ki-
nase/p70S6 kinase pathway, which will in turn counteract the
positive regulation of adiponectin by other pathways.
The transcriptional events that underlie the adiponectin gene
expression remain poorly understood. The transcription factor
PPARc, a key regulator of adipogenesis, has been shown to
transactivate adiponectin gene expression [23]. The PPARc
agonist rosiglitazone could increase adiponectin production in
both animals and patients with diabetes [22]. A more recent
study has mapped the PPARc-responsive elements to a DNA
fragment between )285 and )273 of the human adiponectin
gene [29]. Nevertheless, our current study suggests that PPARc
is not involved in GH-induced gene expression. This notion is
supported by the fact that co-incubation of adipocytes with
rosiglitazone and GH had additive eﬀect on induction of
adiponectin gene expression and that the activity of a 1.0 kb
adiponectin gene promoter was increased by rosiglitazone, but
not by GH (Fig. 4). Given that GHs action on adiponectin is
chronic (Fig. 2) and that it has no eﬀect on the activity of the
)1.0 kb mouse adiponectin gene promoter, it is possible that
this hormone might increase steady state mRNA abundance of
adiponectin gene by enhancing its stability and preventing its
degradation. In line with this speculation, regulation of
mRNA stability has been proposed to be an important
mechanism by which the expression of the adiponectin gene ismodulated [38]. Nevertheless, our results do not exclude the
possibility that GH transactivates adiponectin gene expression
through a cis-DNA fragment that is outside the )1.0 kb
adiponectin gene promoter region. These possibilities are
currently under investigation in our laboratory.
In summary, we demonstrate for the ﬁrst time that chronic
treatment of GH signiﬁcantly enhances expression of the
anti-diabetic and anti-atherogenic hormone adiponectin. In-
terestingly, a recent report found that GH is also the positive
regulator of the newly identiﬁed adiponectin receptors [39],
suggesting that regulation of the adiponectin pathway might
represent an important aspect of GH actions. Many recent
studies have shown that adiponectin replacement therapy
might represent a novel strategy for the treatment of a variety
of diseases, including insulin resistance, type 2 diabetes, ath-
erosclerosis and liver diseases [5–8]. However, the adiponectin
protein based-therapy is limited by the fact that the circulating
concentration of adiponectin (5–30 lg/ml) is very high [14],
which would require large quantity of the recombinant
protein. Further investigation of the signaling pathways that
underlie GH-induced adiponectin gene expression might help
to design novel therapeutic strategies that act through in-
creasing endogenous adiponectin production.
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